<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001997</url>
  </required_header>
  <id_info>
    <org_study_id>072B</org_study_id>
    <secondary_id>CS-PG91-07</secondary_id>
    <nct_id>NCT00001997</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine or Dideoxyinosine in HIV Positive, Asymptomatic and Symptomatic Individuals</brief_title>
  <official_title>Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine or Dideoxyinosine in HIV Positive, Asymptomatic and Symptomatic Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiron Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To investigate the safety of polyethylene glycolated interleukin-2 (PEG IL-2) given&#xD;
      subcutaneously in conjunction with antiviral treatment and to explore the effects of&#xD;
      treatment on surrogate markers of efficacy and incidence of opportunistic infection and other&#xD;
      clinical markers of HIV disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Four escalating doses of PEG IL-2 are studied. Patients are stratified by CD4 level. CD4&#xD;
      levels in Group A are 200 to 500 cells/mm3; in Group B - 1 to less than 200 cells/mm3.&#xD;
      Further stratification is by p24 positive or negative, antiviral therapy for more or less&#xD;
      than a year, and zidovudine (AZT) versus didanosine (ddI). The duration of PEG IL-2 treatment&#xD;
      is a maximum of 28 weeks. This is an outpatient study; patients will be observed for four&#xD;
      hours after the first dose of PEG IL-2 and for one hour after subsequent doses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin-2, Polyethylene Glycolated</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV seropositivity by commercially available ELISA.&#xD;
&#xD;
          -  Meet Disease Status criteria.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Concurrent neoplasms other than basal cell carcinoma of the skin, in-situ carcinoma of&#xD;
             the cervix or limited cutaneous Kaposi's sarcoma.&#xD;
&#xD;
          -  Recently treated HIV-related lymphoma.&#xD;
&#xD;
          -  Major organ allograft.&#xD;
&#xD;
          -  Presence of space occupying central nervous system (CNS) lesions or other conditions&#xD;
             which would be anticipated to cause cerebral edema.&#xD;
&#xD;
          -  Renal compromise or use of drug therapy anticipated to lead to renal compromise.&#xD;
&#xD;
          -  Active opportunistic infection requiring hospitalization or exclude medication.&#xD;
&#xD;
          -  Requiring continual acyclovir for suppression of herpes infection.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Acyclovir.&#xD;
&#xD;
          -  Drug therapy anticipated to lead to renal compromise.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Intolerance to zidovudine (AZT) at 300 mg/day divided q8h or didanosine (ddI) at 7&#xD;
             mg/kg/day given twice a day.&#xD;
&#xD;
          -  History of HIV-related lymphoma.&#xD;
&#xD;
          -  History of asthma requiring frequent therapy, chronic pulmonary disease, hypertension&#xD;
             requiring therapy, or congestive heart failure.&#xD;
&#xD;
          -  Any of the symptoms or conditions listed in Exclusion - Co-Existing Conditions.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        - Any prior therapy with interleukin-2 (IL-2) or PEG IL-2.&#xD;
&#xD;
        Excluded 30 days prior to study entry:&#xD;
&#xD;
        - Treatment with other anti-HIV medication or known immunomodulators or other chemotherapy&#xD;
        or radiation therapy.&#xD;
&#xD;
        Active substance abuse so patients would be anticipated to be poorly compliant with&#xD;
        protocol requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dr David R Senechek</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 1991</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Recombinant Proteins</keyword>
  <keyword>Polyethylene Glycols</keyword>
  <keyword>Interleukin-2</keyword>
  <keyword>Didanosine</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>HIV Seropositivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Didanosine</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

